Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples.
Uložené v:
| Názov: | Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples. |
|---|---|
| Autori: | Opota, O., Brouillet, R., Greub, G., Jaton, K. |
| Rok vydania: | 2025 |
| Zbierka: | Université de Lausanne (UNIL): Serval - Serveur académique lausannois |
| Predmety: | Betacoronavirus/isolation & purification, COVID-19, Coronavirus Infections/diagnosis, Coronavirus Infections/virology, High-Throughput Nucleotide Sequencing/methods, Humans, Molecular Diagnostic Techniques/instrumentation, Molecular Diagnostic Techniques/methods, Nasopharynx/virology, Pandemics, Pneumonia, Viral/diagnosis, Viral/virology, Reverse Transcriptase Polymerase Chain Reaction/methods, SARS-CoV-2, RT-PCR, molecular diagnostic, anal swab, anorectal swab, bronchial aspirate, bronchoalveolar lavage, cobas 6800, nasopharyngeal swab |
| Popis: | In order to cope with the rapid spread of the COVID-19 pandemic, we introduced on our in-house high-throughput molecular diagnostic platform (MDx Platform) a real-time reverse transcriptase PCR (RT-PCR) to detect the SARS-CoV-2 from any clinical specimens. The aim of this study was to compare the RT-PCR results obtain with the MDx Platform and the commercial assay cobas SARS-CoV-2 (Roche) on nasopharyngeal swab and other clinical specimens including sputum, bronchial aspirate, bronchoalveolar lavage and anal swabs. Samples received in our laboratory from patients suspected of COVID-19 (n = 262) were tested in parallel with our MDx platform SARS-CoV-2 PCR and with the cobas SARS-CoV-2 test. The overall agreement between the two tests for all samples tested was 99.24% (260/262), which corresponded to agreements of 100% (178/178) on nasopharyngeal swabs, 95.45% (42/44) on lower respiratory tract specimen with discordant resultS obtained for very high cycle threshold (Ct) value and 100% (40/40) on anorectal swabs. The Ct values for nasopharyngeal swabs displayed an excellent correlation (R2 > 96%) between both tests. The high agreements between the cobas SARS-CoV-2 test and the MDx platform supports the use of both methods for the diagnostic of COVID-19 on various clinical samples. Very few discrepant results may occur at very low viral load. |
| Druh dokumentu: | article in journal/newspaper |
| Popis súboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 2049-632X 33030200 |
| Relation: | Pathogens and Disease; https://iris.unil.ch/handle/iris/118053; serval:BIB_50F61B3E6CFD; 000593394900006 |
| DOI: | 10.1093/femspd/ftaa061 |
| Dostupnosť: | https://iris.unil.ch/handle/iris/118053 https://doi.org/10.1093/femspd/ftaa061 |
| Prístupové číslo: | edsbas.1F8C42F0 |
| Databáza: | BASE |
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | In order to cope with the rapid spread of the COVID-19 pandemic, we introduced on our in-house high-throughput molecular diagnostic platform (MDx Platform) a real-time reverse transcriptase PCR (RT-PCR) to detect the SARS-CoV-2 from any clinical specimens. The aim of this study was to compare the RT-PCR results obtain with the MDx Platform and the commercial assay cobas SARS-CoV-2 (Roche) on nasopharyngeal swab and other clinical specimens including sputum, bronchial aspirate, bronchoalveolar lavage and anal swabs. Samples received in our laboratory from patients suspected of COVID-19 (n = 262) were tested in parallel with our MDx platform SARS-CoV-2 PCR and with the cobas SARS-CoV-2 test. The overall agreement between the two tests for all samples tested was 99.24% (260/262), which corresponded to agreements of 100% (178/178) on nasopharyngeal swabs, 95.45% (42/44) on lower respiratory tract specimen with discordant resultS obtained for very high cycle threshold (Ct) value and 100% (40/40) on anorectal swabs. The Ct values for nasopharyngeal swabs displayed an excellent correlation (R2 > 96%) between both tests. The high agreements between the cobas SARS-CoV-2 test and the MDx platform supports the use of both methods for the diagnostic of COVID-19 on various clinical samples. Very few discrepant results may occur at very low viral load. |
|---|---|
| ISSN: | 2049632X 33030200 |
| DOI: | 10.1093/femspd/ftaa061 |